期刊文献+

异烟肼片微生物限度检查法的建立 被引量:2

Establishment of Microbial Limit Test of Isoniazid Tablets
下载PDF
导出
摘要 建立一种适用于异烟肼片的微生物限度检查方法,并对方法进行验证。需氧菌、霉菌和酵母菌总数计数法、控制菌(大肠埃希菌)检查均采用薄膜过滤法,供试液浓度为1∶10。需氧菌总数、霉菌和酵母菌总数计数法方法验证各试验菌的回收试验结果均在0.5~2.0之间,大肠埃希菌检查法适用性试验符合要求。该方法可行性强,适用于异烟肼片的微生物限度检查。 To establish a microbiological limit test method for isoniazid tablets and verify the method.The total count of aerobic microbial,mold and yeasts,as well as the control bacteria test method,used the membrane filtration method.The test liquid concentration was 1∶10.The recoveries of each validation strain for the total aerobic microbiac count,total yeasts and mold count were were between 0.5 and 2.0.The suitability test of Escherichia coli conforms to the requirements.This method is feasible and applicable to the microbial limit test of isoniazid tablets.
作者 肖中元 周玲 杨红涛 陈真文 马迪 Xiao Zhongyuan;Zhou Ling;Yang Hongtao;Chen Zhenwen;Ma Di(TAIJI Group·Southwest Pharmaceutical Co.,Ltd.,Chongqing 400038,China)
出处 《山东化工》 CAS 2019年第15期111-112,119,共3页 Shandong Chemical Industry
关键词 异烟肼片 微生物限度检查 薄膜过滤法 Isoniazid Tablets microbial limit test membrane filtration method
  • 相关文献

参考文献2

二级参考文献14

  • 1Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010[J]. Eur Respir J,2011,37(2) :441 -462.
  • 2Tang S,Zhang Q,Yu J,et al. Extensively Drug-Resistant Tuberculosis, China[J].Emerging Infectious Diseases,2011,17 (3 ) :558 -560.
  • 3Yaldiz S,Gursoy S,Ucvet A,et al. Surgery offers high cure rates in multidrug-resistant tuberculosis [ J ]. Ann Thorac Cardiovasc Surg, 2011,17(2) :143 -147.
  • 4World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis : 2011 update [ R ].Geneva, World Health Organization, WHO/HTM/TB ,2011.
  • 5Ma Z,Lienhardt C,Mcllleron H,et al. Global tuberculosis drug development pipeline : the need and the reality[ J].Lancet,2010,375 : 2100-2109.
  • 6Tang SJ,Zhang Q,Zeng LH,et al. Efficacy and safety of linezolid for the treatment of extensively drug resistant tuberculosis [ J ].Jpn I Infect Dis ,2011,64:488 - 492.
  • 7Singh V, Mani I, Chaudhary DK, et al. The p-ketoacyl-ACP synthase from Mycobacterium tuberculosis as potential drug targets [J].Curr Med Chem,2011,18(9) :1318 - 1324.
  • 8Dheda K,Schwander SK, Zhu B,et al. The immunology of tuberculosis: from bench to bedside[ J].Respirology,2010,15(3) :433 -450.
  • 9Dlugovitzky D,Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB[ J]. Immunotherapy,2011,3(4) :557 -568.
  • 10Butov DA,Pashkov YN,Stepanenko AL, et al. Phase H b randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis,relapsed and multi-drug-resistant ( MDR ) TB [ J ].J Immune Based Ther Vaccines ,2011,9:3.

共引文献25

同被引文献44

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部